Get Updates

Research & Clinical Trials

As the only national nonprofit advocacy organization focused on hereditary breast and ovarian cancer, FORCE has a strong commitment to promoting research.

| More


Phase I Study of ABT-888 (veliparib) in Combination With Cisplatin and Vinorelbine for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer

Study identifier: NCT01104259
Full study details on

Name of PARP Inhibitor used in study:

Veliparib (Abbott)


  • Patients with recurrent and/or metastatic triple negative breast cancer or BRCA1 or BRCA2 mutation and recurrent and/or metastatic breast cancer
  • Subjects must have measurable disease, defined as at least one lesion that can be measured in at least one dimension; this includes measurable (bi-dimensional) chest wall disease and/or cutaneous metastatic lesions at least 10 mm

Type of study:

Phase I study


Patients receive oral ABT-888 twice daily on days 1-14 (days 0-13 of course 1 only). Patients also receive cisplatin IV and vinorelbine IV on days 1 and 8. Treatment repeats every 21 days for 6- 10 courses in the absence of disease progression or unacceptable toxicity. Treatment with ABT-888 alone may continue in the absence of disease progression or unacceptable toxicity.

Study site:


Fred Hutchinson Cancer Research Center/University of Washington Cancer
Seattle, Washington, 98109
Contact: Phase I Program 206-288-7551       
Principal Investigator: John Thompson


Page updated 07/08/13

FORCE:Facing Our Risk of Cancer Empowered